Cargando…

Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study

BACKGOUND: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a subtype of RCC that is increasingly recognized pathologically. The aim of this study was to evaluate the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positro...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikolovski, Ines, Carlo, Maria I., Chen, Ying-Bei, Vargas, Hebert Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893914/
https://www.ncbi.nlm.nih.gov/pubmed/33608050
http://dx.doi.org/10.1186/s40644-021-00392-9
_version_ 1783653142723821568
author Nikolovski, Ines
Carlo, Maria I.
Chen, Ying-Bei
Vargas, Hebert Alberto
author_facet Nikolovski, Ines
Carlo, Maria I.
Chen, Ying-Bei
Vargas, Hebert Alberto
author_sort Nikolovski, Ines
collection PubMed
description BACKGOUND: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a subtype of RCC that is increasingly recognized pathologically. The aim of this study was to evaluate the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG PET), and to determine the pre-operative diagnostic potential of imaging. METHODS: This single-site retrospective study included patients with histologically confirmed FH-RCC or with a renal cancer and known germline FH mutation; imaging of the renal mass before treatment with contrast-enhanced CT, contrast-enhanced MRI, or FDG PET/CT between October 2007 and May 2019. Clinical information, pathological data, and imaging features were analyzed and reported descriptively. RESULTS: Sixteen patients with sixteen tumors were included (median age 46 years, interquartile range 38–53 years; 31 % female). Almost all tumors were unifocal (15/16, 94 %). Most tumors had infiltrative margins (14/16, 88 %); few were circumscribed (2/16, 12 %). A large cystic tumor component (> 75 % of tumor volume) was seen in 8/16 (50 %) of tumors. Involvement of renal sinus fat was seen in 13/16 (81 %) of tumors, involvement of the hilar collecting system in 8/16 (50 %), and renal vein tumor thrombus in 6/16 (38 %). All 12 tumors (100 %) imaged with MRI had heterogenous tumor enhancement and heterogenous T2 signal. Of those patients that had diffusion-weighted imaging, 11/11 (100 %) of tumors had diffusion restriction in the solid portions of the tumor. Of the patients who had PET, 3/3 (100 %) tumors showed high metabolic activity with mean maximum standardized uptake value (SUV(max)) of 16.4 (range 9.6–21.9). Patients presented with retroperitoneal nodal metastases in 69 % of cases and distant metastases in 75 %. Of those four patients without metastatic disease at presentation, three (75 %) developed metastases within 4 years of diagnosis. CONCLUSIONS: In our study, the majority of tumors (≥ 75 %) were unifocal, had an infiltrative margin, invaded the renal sinus fat, and presented with distant metastases. On MRI, most tumors had heterogenous T2 signal and diffusion restriction in their solid components. The small number of cases that had PET imaging showed high metabolic activity.
format Online
Article
Text
id pubmed-7893914
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78939142021-02-22 Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study Nikolovski, Ines Carlo, Maria I. Chen, Ying-Bei Vargas, Hebert Alberto Cancer Imaging Research Article BACKGOUND: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a subtype of RCC that is increasingly recognized pathologically. The aim of this study was to evaluate the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG PET), and to determine the pre-operative diagnostic potential of imaging. METHODS: This single-site retrospective study included patients with histologically confirmed FH-RCC or with a renal cancer and known germline FH mutation; imaging of the renal mass before treatment with contrast-enhanced CT, contrast-enhanced MRI, or FDG PET/CT between October 2007 and May 2019. Clinical information, pathological data, and imaging features were analyzed and reported descriptively. RESULTS: Sixteen patients with sixteen tumors were included (median age 46 years, interquartile range 38–53 years; 31 % female). Almost all tumors were unifocal (15/16, 94 %). Most tumors had infiltrative margins (14/16, 88 %); few were circumscribed (2/16, 12 %). A large cystic tumor component (> 75 % of tumor volume) was seen in 8/16 (50 %) of tumors. Involvement of renal sinus fat was seen in 13/16 (81 %) of tumors, involvement of the hilar collecting system in 8/16 (50 %), and renal vein tumor thrombus in 6/16 (38 %). All 12 tumors (100 %) imaged with MRI had heterogenous tumor enhancement and heterogenous T2 signal. Of those patients that had diffusion-weighted imaging, 11/11 (100 %) of tumors had diffusion restriction in the solid portions of the tumor. Of the patients who had PET, 3/3 (100 %) tumors showed high metabolic activity with mean maximum standardized uptake value (SUV(max)) of 16.4 (range 9.6–21.9). Patients presented with retroperitoneal nodal metastases in 69 % of cases and distant metastases in 75 %. Of those four patients without metastatic disease at presentation, three (75 %) developed metastases within 4 years of diagnosis. CONCLUSIONS: In our study, the majority of tumors (≥ 75 %) were unifocal, had an infiltrative margin, invaded the renal sinus fat, and presented with distant metastases. On MRI, most tumors had heterogenous T2 signal and diffusion restriction in their solid components. The small number of cases that had PET imaging showed high metabolic activity. BioMed Central 2021-02-19 /pmc/articles/PMC7893914/ /pubmed/33608050 http://dx.doi.org/10.1186/s40644-021-00392-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Nikolovski, Ines
Carlo, Maria I.
Chen, Ying-Bei
Vargas, Hebert Alberto
Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
title Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
title_full Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
title_fullStr Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
title_full_unstemmed Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
title_short Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
title_sort imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893914/
https://www.ncbi.nlm.nih.gov/pubmed/33608050
http://dx.doi.org/10.1186/s40644-021-00392-9
work_keys_str_mv AT nikolovskiines imagingfeaturesoffumaratehydratasedeficientrenalcellcarcinomasaretrospectivestudy
AT carlomariai imagingfeaturesoffumaratehydratasedeficientrenalcellcarcinomasaretrospectivestudy
AT chenyingbei imagingfeaturesoffumaratehydratasedeficientrenalcellcarcinomasaretrospectivestudy
AT vargashebertalberto imagingfeaturesoffumaratehydratasedeficientrenalcellcarcinomasaretrospectivestudy